Related Experiment Videos
HIV-1 protease inhibitors in development
Stefano Rusconi1, Simona La Seta Catamancio
1Istituto di Malattie Infettive e Tropicali, Universita' di Milano, Ospedale Luigi Sacco, via GB Grassi 74, 20157 Milano, Italy. rusconi@mailserver.unimi.it
Expert Opinion on Investigational Drugs
|February 28, 2002
Summary
New protease inhibitors (PI) combat HIV-1 drug resistance. Second-generation PIs show promise in overcoming cross-resistance, with third-generation drugs in development offering future treatment options.
Area of Science:
- Pharmaceuticals
- Virology
- Drug Development
Background:
- Second-generation protease inhibitors (PI) have been developed to address cross-resistance in HIV-1 treatment.
- These new compounds are designed for improved absorption and efficacy.
- The emergence of PI cross-resistance necessitates the development of novel therapeutic agents.
Purpose of the Study:
- To review third-generation protease inhibitors currently in development.
- To assess the clinical and antiviral efficacy of new PI molecules compared to older ones.
Main Methods:
- Review of preclinical and clinical trial data for second-generation PIs.
- Analysis of ongoing comparative trials for third-generation PIs.
Main Results:
- Second-generation PIs are designed to overcome cross-resistance.
- Comparative trials are underway to evaluate new PI efficacy.
Conclusions:
- Clinicians will require new active PIs due to rapid cross-resistance development.
- Third-generation PIs are expected to provide crucial advancements in HIV-1 treatment.